Zensun´s rhNRG-1 Project has passed the Preliminary Evaluation by Boehringer-Ingelheim
2006-03-02
In April 15, 2003, Boehringer-Ingelheim finished the preliminary evaluation of anti-heart failure drug—rhNRG-1. In late April, more detailed data was provided by Zensun to undergo the second round of evaluation.
更多动态
Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to
